Sept. 2022

Prostate cancer (PC) is a leading cause of morbidity and mortality among men worldwide. One major issue in PCa research is to accurately distinguish between indolent and clinically significant (csPCa) to reduce overdiagnosis and overtreatment. 

A new study was published, dealing with the validation of diagnostic nomograms (DN) based on proteomic urinary biomarkers to detect clinically significant prostate cancer.

Independent validation of the 19-biomarker model (BM) resulted in an 87% sensitivity and 65% specificity, with an AUC of 0.81, outperforming PSA (AUC _PSA: 0.64), PSA density (AUC _PSAD: 0.64) and ERSPC-3/4 risk calculator (0.67). Integration of the 19-BM with the rest clinical variables into distinct DN, resulted in improved (AUC range: 0.82-0.88) but not significantly better performances over 19-BM alone. Thus, 19-BM alone or upon integration with clinical variables into DN, might be useful for detecting csPCa by decreasing the number of biopsies.